| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-07 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-06 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.15 | 6e-06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.21 | 1e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-05 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.15 | 2e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |